İdiyopatik pulmoner fibroziste cinsiyet, yaş, fizyoloji indeksi ve C-reaktif protein/albumin oranının prognostik rolü

Yıl 2020, Cilt: 3 Sayı: 3, 317 - 323, 18.06.2020

Derya Yenibertiz Berna Akıncı Özyürek Sertaç Büyükyaylacı Özden Aslıhan Gürün Kaya Yurdanur Erdoğan

https://doi.org/10.32322/jhsm.738446

Öz

Amaç: Bu çalışmada idiopatik pulmoner fibrosisli hastaların prognozu, klinik seyri ve sağkalımını değerlendirmek için cinsiyet, yaş ve fizyoloji indeksi ve C-reaktif protein/albümin oranını karşılaştırmayı amaçladık.
Gereç ve Yöntem: Ocak 2013- Aralık 2018 tarihleri arasında hastanemizin 8. kliniğinde radyolojik veya patolojik olarak tanı konulmuş olan 47 idiopatik pulmoner fibrosis hastası çalışmaya dahil edildi. Hastaların demografik özellikleri, solunum fonksiyon testleri, 6 dakika yürüme testi değerleri, Ekokardiyografi sonuçları, yaşam süreleri, ek hastalıkları, tedavi bilgileri, laboratuvar sonuçları, cinsiyet, yaş ve fizyoloji indeksleri ve başlangıç C-reaktif protein/albümin oranları hasta dosyalarından kaydedildi.
Bulgular: Cinsiyet, yaş ve fizyoloji indeksine göre evre I’de 25 (%53,2) hasta, evre II’de 11 (%23,4) hasta ve evre III’te 11 (%23,4) hasta vardı. Hastalar yaşam durumlarına göre 2 gruba ayrıldı. Eksitus olan grupta solunum yetmezliği, ortalama pulmoner arter basıncı ve cinsiyet, yaş ve fizyoloji evresi anlamlı olarak yüksekti (p<0,05). 6 dakikalık yürüme testi eksitus grubunda anlamlı olarak düşüktü (p<0,05). C-reaktif protein/albümin oranı sonuçları her iki grupta benzerdi ve her iki grupta da diğer parametreler açısından anlamlı farklılık yoktu.
Sonuç: Cinsiyet, yaş ve fizyoloji evresi kolay ve kullanışlıdır, ancak C-reaktif protein/albümin oranı idiopatik pulmoner fibrosisin prognozunu tahmin etmek için uygun değildir. Pulmoner arter basıncının yüksekliği, düşük 6 dakikalık yürüme testi sonuçları ve solunum yetmezliğinin varlığı idiopatik pulmoner fibrosisde kötü prognostik faktörlerdir.

Anahtar Kelimeler

İdiopatik pulmoner fibrosis, İPF, GAP indeksi, CAR

The prognostic role of gender, age and physiology index and C-reactive protein/albumin ratio in idiopathic pulmonary fibrosis

Öz

Aim: We aimed to compare the gender, age, and physiology index and C-reactive protein/albumin ratio in order to evaluate the prognosis, clinical course and survival of patients with idiopathic pulmonary fibrosis.
Material and Method: Forty-seven patients with idiopathic pulmonary fibrosis diagnosed by radiologically or pathologically in the 8th clinic of our hospital between January 2013 and December 2018 included to the study. Demographic characteristics, pulmonary function tests, 6-minute walk test values, echocardiography results, life span, additional diseases, treatment information, laboratory results of patients, gender, age and physiology indexes and initial C-reactive protein/albumin ratio of the patients were recorded from the patient files.
Results: According to gender, age and physiology index there were 25 (53.2%) patients in stage I, 11 (23.4%) patients in stage II, and 11 (23.4%) patients in stage III. The patients were divided into 2 groups according to their life conditions. The rate of respiratory failure, the mean pulmonary arterial pressure and gender, age, and physiology stage were significantly higher (p grup 0.05) in the exitus group. The 6- minute walk test was significantly lower in the exitus group (p<0.05). C-reactive protein/albumin ratio results were similar in both groups and there were no significant differences according to other parameters in both groups too. There was no significant difference between the C-reactive protein/albumin ratio values of the patients in each of the three gender, age, and physiology stages.
Conclusion: Gender, age, and physiology stage is easy and useful but C-reactive protein/albumin ratio isn’t convenient to predict the prognosis of idiopathic pulmonary fibrosis. The elevation of pulmonary arterial pressure, low 6 minute walk test and presence of respiratory failure are poor prognostic factors in idiopathic pulmonary fibrosis.

Anahtar Kelimeler

Idiopathic pulmonary fibrosis, IPF, GAP stage, CRP/Albumin ratio (CAR)

Kaynakça

• 1. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788–824.
• 2. Jo HE, Glaspole I, Grainge C, et al. Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian idiopathic pulmonary fibrosis registry. Eur Respir J 2017; 49: pii: 1601592
• 3. Hutchinson J. Idiopathic pulmonary fibrosis: another step in understanding the burden of this disease. Eur Respir J 2016; 48: 26–28.
• 4. Marshall DC, Salciccioli JD, Shea BS, Akuthota P. Trends in mortality from idiopathic pulmonary fibrosis in the European Union: an observational study of the WHO mortality database from 2001–2013. Eur Respir J 2018; 51: pii: 1701603.
• 5. Navaratnam V, Fleming KM, West J, et al. The rising incidence of idiopathic pulmonary fibrosis in the U.K. Thorax 2011; 66: 462–67.
• 6. Algranti E, Saito CA, Silva D, Carneiro APS, Bussacos MA. Mortality from idiopathic pulmonary fibrosis: a temporal trend analysis in Brazil, 1979–2014. J Bras Pneumol 2017; 43: 445–50.
• 7. Ley B, Ryerson CJ, Vittinghoff E, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med 2012; 156: 684–95.
• 8. Meyer KC. New treatments for idiopathic pulmonary fibrosis. Clinical Pulmonary Medicine. 2016; 23: 241-51.
• 9. Liu Z, Jin K, Guo M, et al. Prognostic value of the CRP/Alb ratio, a novel inflammation-based score in pancreatic cancer. Ann Surg Oncol 2017; 24: 561–68.
• 10. Zhang Y, Zhou GQ, Liu X, et al. Exploration and validation of C-reactive protein/albumin ratio as a novel inflammation-based prognostic marker in nasopharyngeal carcinoma. J Cancer 2016; 7: 1406–12.
• 11. Shibutani M, Maeda K, Nagahara H, et al. Prognostic significance of the preoperative ratio of C-reactive protein to albumin in patients with colorectal cancer. Anticancer Res 2016; 36: 995–1001.
• 12. Xu XL, Yu HQ, Hu W, Song Q, Mao WM. A novel inflammation-based prognostic score, the C-reactive protein/albumin ratio predicts the prognosis of patients with operable esophageal squamous cell carcinoma. PLoS One 2015; 10: e0138657.
• 13. Zhang F, Ying L, Jin J, et al. The C-reactive protein/albumin ratio predicts long-term outcomes of patients with operable non-small cell lung cancer. Oncotarget 2017; 8: 8835–42.
• 14. Miyazaki T, Yamasaki N, Tsuchiya T, et al. Ratio of C-reactive protein to albumin is a prognostic factor for operable non-small-cell lung cancer in elderly patients. Surg Today 2016; 47: 836-43.
• 15. Zhou T, Zhan J, Hong S, et al. Ratio of C-reactive protein/albumin is an inflammatory prognostic score for predicting overall survival of patients with small-cell lung cancer. Sci Rep 2015; 5: 10481.
• 16. Young W. Koh, Hyun W. Prognostic impact of C-reactive protein/albumin ratio on the overall survival of patients with advanced nonsmall cell lung cancers receiving palliative chemotherapy. Lee Medicine (Baltimore) 2017; 96: e6848.
• 17. Sun P, Chen C, Xia Y, et al. The ratio of c-reactive protein/albumin is a novel ınflammatory predictor of overall survival in cisplatin-based treated patients with metastatic nasopharyngeal carcinoma. Dis Markers 2017; 2017: 6570808.
• 18. Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011; 183: 431-40.
• 19. Salisbury ML, Xia M, Zhou Y, et al. Idiopathic pulmonary fibrosis: gender-age-physiology ındex stage for predicting future lung function decline. Chest 2016; 149: 491-98.
• 20. Lee SH, Park JS, Kim SY, et al. Comparison of CPI and GAP models in patients with idiopathic pulmonary fibrosis: a nationwide cohort study. Sci Rep 2018; 8: 4784.
• 21. Song MJ, Lim SY, Park JS, et al. Prognosis of small cell lung cancer with ıdiopathic pulmonary fibrosis: assessment according to GAP stage. J Oncol 2019; 2019: 5437390
• 22. Kim HJ, Perlman D, Tomic R. Natural history of idiopathic pulmonary fibrosis. Respir Med 2015; 109: 661–70.
• 23. Beydon N, Davis SD, Lombardi E, et al. American Thoracic Society/European Respiratory Society Working Group on ınfant and young children pulmonary function testing. an official American Thoracic Society/European Respiratory Society statement: pulmonary function testing in preschool children. Am J Respir Crit Care Med 2007; 175: 1304–45.
• 24. Song H, Sun D, Ban C, et al. Independent clinical factors relevant to prognosis of patients with ıdiopathic pulmonary fibrosis. Med Sci Monit 2019; 25: 4193–201.
• 25. Olson AL, Swigris JJ, Lezotte DC, et al. Mortality from pulmonary fibrosis increased in the United States from 1992 to 2003. Am J Respir Crit Care Med 2007; 176: 277–84.
• 26. Fairclough E., Cairns E., Hamilton J. & Kelly C. Evaluation of a modified early warning system for acute medical admissions and comparison with C-reactive protein/albumin ratio as a predictor of patient outcome. Clin. Med. 9,2009; 30–33.
• 27. Cai M, Zhu M, Ban C, et al. Clinical features and outcomes of 210 patients with idiopathic pulmonary fibrosis. Chin Med J (Engl) 2014; 127: 1868–73.
• 28. Caminati A, Bianchi A, Cassandro R, Mirenda MR, Harari S. Walking distance on 6-MWT is a prognostic factor in idiopathic pulmonary fibrosis. Respir Med 2009; 103: 117-23.